Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics
Rajshekhar Chakraborty(Columbia University Irving Medical Center), Morie A. Gertz(Medical University of South Carolina), Francis K. Buadi, Nelson Leung(WinnMed), Dragan Jevremović(Mayo Clinic in Arizona), Shaji Kumar(Mayo Clinic), Prashant Kapoor, Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), William J. Hogan(Mayo Clinic), Angela Dispenzieri(Mayo Clinic), Suzanne R. Hayman, David Dingli
Cited by 57
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k